Fig. 3

PRMT5 promotes PCa progression through the PRMT5-CAMK2N1 axis. A and B CCK-8 and plate colony-formation assays were performed to determine the proliferation abilities of PC-3 and DU145 cells treated with control, sh_PRMT5, or sh_PRMT5 + sh_CAMK2N1. C Image of subcutaneous xenografts in control, sh_PRMT5, sh_PRMT5 + sh_CAMK2N1 groups. D The tumor growth curves of xenografts were plotted in control, sh_PRMT5, sh_PRMT5 + sh_CAMK2N1 groups. E Representative IHC staining micrographs of Ki-67 in tumor xenografts were conducted. Scale bar = 20 μm. F and G Wound healing and transwell assays were performed to determine the migratory capabilities of PC-3 and DU145 cells treated with control, sh_PRMT5, sh_PRMT5 + sh_CAMK2N1. H BALB/c nude mice injected with cells (control, sh_PRMT5, sh_PRMT5 + sh_CAMK2N1; Five mice per group) via tail vein were imaged at 40 days by in vivo imaging system to evaluate the whole metastasis. I Representative images of H&E staining of lung metastasis loci. Data were showed as mean ± SD. **P < 0.01